Curia to Expand U.S. Commercial Manufacturing Capability
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced plans to expand its commercial manufacturing capacity at its Rensselaer, New York facility. The increased capability to flexibly manufacture complex Active Pharmaceutical Ingredients (APIs) will further strengthen Curia’s ability to partner with customers, meeting small-scale to large-volume requirements with reliable delivery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210819005107/en/
Curia is investing more than $35 million in these state-of-the-art expanded manufacturing and product-handling solutions for complex small molecules. The expansion will include new vessel capacities that more than double the site’s batch-size scaling and product output. It will allow for the introduction of a variety of new products and enable Curia to meet growing demand for high potency API manufacturing.
The expansion will generate new technical jobs in Rensselaer. Consistent with Curia’s commitment to environmental stewardship, the expansion plans include optimization of energy usage and enhanced environmental standards as integral elements.
“Our Rensselaer team’s history of excellence in delivering U.S.-based complex manufacturing solutions that enable our customers to provide vital treatments to patients is resulting in increasing demand,” said Curia Chairman and CEO John Ratliff. “Some of the life-saving products produced at Rensselaer are highly complex, including critical oncology therapeutics and novel treatments addressing unmet medical needs. The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”
Curia’s Rensselaer facility has provided high-quality APIs to global pharmaceutical companies for more than 100 years. The site currently produces APIs to meet the development and commercial needs of more than 50 products. It was the first facility in the industry to be designated “Industry Leader” as part of its re-certification under the independent SafeBridge® program for “Potent Compound Safety Certification” in 2020.
The expansion is expected to be completed within 18 months, adding to Curia’s existing breadth of API manufacturing facilities in the U.S., France, Spain, Italy and India, each supporting flexible manufacturing solutions for orders ranging from grams to metric tons, to provide seamless support to customers along the R&D and manufacturing continuum.
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,400 employees at 23 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-WIPRO-LIMITED26.9.2021 14:59:11 CEST | Press release
Spirit of Wipro Run Brings Together Participants From Over 35 Countries
PENCIL-LAB25.9.2021 12:06:07 CEST | Press release
Pencil Lab Inks Debut in ADIHEX 2021
VA-DXC-TECHNOLOGY24.9.2021 22:32:17 CEST | Press release
DXC Technology Completes Refinancing Actions
TX-SCHLUMBERGER24.9.2021 16:02:07 CEST | Press release
Schlumberger Announces Third-Quarter 2021 Results Conference Call
TRADEWEB-MARKETS24.9.2021 14:09:08 CEST | Press release
Tradeweb Successfully Completes its First Southbound Bond Connect Transactions
FL-H.I.G.-CAPITAL24.9.2021 14:07:08 CEST | Press release
H.I.G. Capital Acquires Aspire Pharma
TRUSTSWAP24.9.2021 13:36:11 CEST | Press release
Swappable Announces Partnership with Esports T1's Dota 2 Team
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom